A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men

Effects on bone metabolism

Luigi Gennari, Laura Masi, Daniela Merlotti, Lucia Picariello, Alberto Falchetti, Annalisa Tanini, Carmelo Mavilia, Francesca Del Monte, Stefano Gonnelli, Barbara Lucani, Carlo Gennari, Maria Luisa Brandi

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

Current evidence suggests that estrogen plays a dominant role in determining bone mineral density (BMD) in men, and inactivating mutations in the aromatase CYP19 gene have been associated with low bone mass in young males. We previously reported an association between a TTTA repeat polymorphism in introa 4 of the CYP19 gene and osteoporotic risk in postmenopausal females. Here we explore the role of this polymorphism as a genetic determinant of BMD in a sample of elderly males who were recruited by direct mailing and followed longitudinally for 2 (n = 300) and 4 (n = 200) yr. Six different allelic variants, containing seven, eight, nine, 10, 11, and 12 TTTA repeats, were detected. There was a bimodal distribution of alleles, with two major peaks at seven and 11 repeats and a very low distribution of the nine-repeat allele. Men with a high-repeat genotype (>nine repeats) showed higher lumbar BMD values, lower bone turnover markers, higher estradiol levels, and a lower rate of BMD change than men with a low-repeat genotype (25), suggesting that the effect of CYP19 genotypes on bone may be masked by the increase in fat mass. Moreover, the high-repeat genotype was less represented, although not significantly, in the vertebral fracture group with respect to the nonvertebral fracture group. Functional in vitro analysis after incubation with [3H]-androstenedione showed a higher aromatase activity in fibroblasts from subjects with a high-repeat genotype than in fibroblasts from subjects with a low-repeat genotype. In conclusion, differences in estrogen levels due to polymorphism at the aromatase CYP19 gene may predispose men to increased age-related bone loss and fracture risk.

Original languageEnglish
Pages (from-to)2803-2810
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Volume89
Issue number6
DOIs
Publication statusPublished - Jun 2004

Fingerprint

Aromatase
Metabolism
Bone
Estrogens
Bone and Bones
Genotype
Bone Density
Minerals
Polymorphism
Genes
Fibroblasts
Alleles
Androstenedione
Bone Remodeling
Bone Fractures
Osteoporosis
Estradiol
Fats
Mutation

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men : Effects on bone metabolism. / Gennari, Luigi; Masi, Laura; Merlotti, Daniela; Picariello, Lucia; Falchetti, Alberto; Tanini, Annalisa; Mavilia, Carmelo; Del Monte, Francesca; Gonnelli, Stefano; Lucani, Barbara; Gennari, Carlo; Brandi, Maria Luisa.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 89, No. 6, 06.2004, p. 2803-2810.

Research output: Contribution to journalArticle

Gennari, L, Masi, L, Merlotti, D, Picariello, L, Falchetti, A, Tanini, A, Mavilia, C, Del Monte, F, Gonnelli, S, Lucani, B, Gennari, C & Brandi, ML 2004, 'A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: Effects on bone metabolism', Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 6, pp. 2803-2810. https://doi.org/10.1210/jc.2003-031342
Gennari, Luigi ; Masi, Laura ; Merlotti, Daniela ; Picariello, Lucia ; Falchetti, Alberto ; Tanini, Annalisa ; Mavilia, Carmelo ; Del Monte, Francesca ; Gonnelli, Stefano ; Lucani, Barbara ; Gennari, Carlo ; Brandi, Maria Luisa. / A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men : Effects on bone metabolism. In: Journal of Clinical Endocrinology and Metabolism. 2004 ; Vol. 89, No. 6. pp. 2803-2810.
@article{4cdd261e736d45eb81c474591bab41ad,
title = "A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: Effects on bone metabolism",
abstract = "Current evidence suggests that estrogen plays a dominant role in determining bone mineral density (BMD) in men, and inactivating mutations in the aromatase CYP19 gene have been associated with low bone mass in young males. We previously reported an association between a TTTA repeat polymorphism in introa 4 of the CYP19 gene and osteoporotic risk in postmenopausal females. Here we explore the role of this polymorphism as a genetic determinant of BMD in a sample of elderly males who were recruited by direct mailing and followed longitudinally for 2 (n = 300) and 4 (n = 200) yr. Six different allelic variants, containing seven, eight, nine, 10, 11, and 12 TTTA repeats, were detected. There was a bimodal distribution of alleles, with two major peaks at seven and 11 repeats and a very low distribution of the nine-repeat allele. Men with a high-repeat genotype (>nine repeats) showed higher lumbar BMD values, lower bone turnover markers, higher estradiol levels, and a lower rate of BMD change than men with a low-repeat genotype (25), suggesting that the effect of CYP19 genotypes on bone may be masked by the increase in fat mass. Moreover, the high-repeat genotype was less represented, although not significantly, in the vertebral fracture group with respect to the nonvertebral fracture group. Functional in vitro analysis after incubation with [3H]-androstenedione showed a higher aromatase activity in fibroblasts from subjects with a high-repeat genotype than in fibroblasts from subjects with a low-repeat genotype. In conclusion, differences in estrogen levels due to polymorphism at the aromatase CYP19 gene may predispose men to increased age-related bone loss and fracture risk.",
author = "Luigi Gennari and Laura Masi and Daniela Merlotti and Lucia Picariello and Alberto Falchetti and Annalisa Tanini and Carmelo Mavilia and {Del Monte}, Francesca and Stefano Gonnelli and Barbara Lucani and Carlo Gennari and Brandi, {Maria Luisa}",
year = "2004",
month = "6",
doi = "10.1210/jc.2003-031342",
language = "English",
volume = "89",
pages = "2803--2810",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men

T2 - Effects on bone metabolism

AU - Gennari, Luigi

AU - Masi, Laura

AU - Merlotti, Daniela

AU - Picariello, Lucia

AU - Falchetti, Alberto

AU - Tanini, Annalisa

AU - Mavilia, Carmelo

AU - Del Monte, Francesca

AU - Gonnelli, Stefano

AU - Lucani, Barbara

AU - Gennari, Carlo

AU - Brandi, Maria Luisa

PY - 2004/6

Y1 - 2004/6

N2 - Current evidence suggests that estrogen plays a dominant role in determining bone mineral density (BMD) in men, and inactivating mutations in the aromatase CYP19 gene have been associated with low bone mass in young males. We previously reported an association between a TTTA repeat polymorphism in introa 4 of the CYP19 gene and osteoporotic risk in postmenopausal females. Here we explore the role of this polymorphism as a genetic determinant of BMD in a sample of elderly males who were recruited by direct mailing and followed longitudinally for 2 (n = 300) and 4 (n = 200) yr. Six different allelic variants, containing seven, eight, nine, 10, 11, and 12 TTTA repeats, were detected. There was a bimodal distribution of alleles, with two major peaks at seven and 11 repeats and a very low distribution of the nine-repeat allele. Men with a high-repeat genotype (>nine repeats) showed higher lumbar BMD values, lower bone turnover markers, higher estradiol levels, and a lower rate of BMD change than men with a low-repeat genotype (25), suggesting that the effect of CYP19 genotypes on bone may be masked by the increase in fat mass. Moreover, the high-repeat genotype was less represented, although not significantly, in the vertebral fracture group with respect to the nonvertebral fracture group. Functional in vitro analysis after incubation with [3H]-androstenedione showed a higher aromatase activity in fibroblasts from subjects with a high-repeat genotype than in fibroblasts from subjects with a low-repeat genotype. In conclusion, differences in estrogen levels due to polymorphism at the aromatase CYP19 gene may predispose men to increased age-related bone loss and fracture risk.

AB - Current evidence suggests that estrogen plays a dominant role in determining bone mineral density (BMD) in men, and inactivating mutations in the aromatase CYP19 gene have been associated with low bone mass in young males. We previously reported an association between a TTTA repeat polymorphism in introa 4 of the CYP19 gene and osteoporotic risk in postmenopausal females. Here we explore the role of this polymorphism as a genetic determinant of BMD in a sample of elderly males who were recruited by direct mailing and followed longitudinally for 2 (n = 300) and 4 (n = 200) yr. Six different allelic variants, containing seven, eight, nine, 10, 11, and 12 TTTA repeats, were detected. There was a bimodal distribution of alleles, with two major peaks at seven and 11 repeats and a very low distribution of the nine-repeat allele. Men with a high-repeat genotype (>nine repeats) showed higher lumbar BMD values, lower bone turnover markers, higher estradiol levels, and a lower rate of BMD change than men with a low-repeat genotype (25), suggesting that the effect of CYP19 genotypes on bone may be masked by the increase in fat mass. Moreover, the high-repeat genotype was less represented, although not significantly, in the vertebral fracture group with respect to the nonvertebral fracture group. Functional in vitro analysis after incubation with [3H]-androstenedione showed a higher aromatase activity in fibroblasts from subjects with a high-repeat genotype than in fibroblasts from subjects with a low-repeat genotype. In conclusion, differences in estrogen levels due to polymorphism at the aromatase CYP19 gene may predispose men to increased age-related bone loss and fracture risk.

UR - http://www.scopus.com/inward/record.url?scp=2942631367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942631367&partnerID=8YFLogxK

U2 - 10.1210/jc.2003-031342

DO - 10.1210/jc.2003-031342

M3 - Article

VL - 89

SP - 2803

EP - 2810

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -